# Sichuan Ingia Biosynthetic Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sichuan-ingia-biosynthetic-co

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.scingia.com
- Latest round: Series A (Sep 19, 2025)
- Investors on record: 2

## About

Based in Chengdu, China and founded in 2015, Sichuan Ingia Biosynthetic Co., Ltd. operates as a synthetic biology technology developer, manufacturing the stevia glycosides by biological method. The company established Chengdu Research and Development Center for Synthetic Biology of Natural Products with Shanghai Institutes of Life Sciences, Chinese Academy of Sciences. The company has obtained more than 20 domestic and foreign patent certifications. In March 2022, the company closed series A funding from new investor Addor Capital. In September 2025, Sichuan Ingia Biosynthetic Co., Ltd. closed series A+ funding from new investor Sinovation Ventures and returning investor Addor Capital.

The products manufactured by the company include stevia glycosides, coenzyme Q10, vanillin, monk fruit glycosides and nicotinamide mononucleotide. The products of the company can be used in making soda water, yoga, bread, cake, biscuit, ice cream and etc. The company generates revenue from providing natural sweeteners, natural flavors and fragrances and dietary supplements products.

The company will focuses on accelerating the company's layout in the field of synthetic biology.

## Funding rounds

- Series A, Sep 19, 2025 — Sinovation Ventures, Addor Capital
- Series A, Mar 2, 2022 — Addor Capital

## Investors

- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series A